Clinical and experimental data indicate that, in the large majority of cancers, TAMs acquire an M2-like tumor-promoting phenotype characterized by high levels of immunosuppressive markers (e.g., ARG1, MMR1, IL10), as opposed to low levels of inflammatory cytokines (e.g., IL-12, IL1β, TNFα) [32,33,34]. Here, TNF is linked to neoplasm.